no antigen loss; in vivo CAR T cell expansion; CAR T tumor infiltration in PD case after IV dose; regression of spinal cord tumor but not metastasis after IV dose; Tregs and MDSCs increase post therapy; dose limiting toxicity for IV but not ICV; manageable TIAN in all patients after ICV infusion correlated with CCL2 upregulation; PD associated with TGF-β upregulation; 57% transduction efficiency. This evidence concerns the gene CCL2 and neoplasm.